Pharma Mar SA 2025 SR
The report details Pharma Mar's sustainability performance and non-financial disclosures for the fiscal year 2025. Key highlights include the company's progress under its Net Zero Plan, achieving a 28.9% reduction in Scope 1 and 2 emissions compared to the 2021 base year. Pharma Mar also expanded its renewable energy capacity by installing 630 kWp of additional solar panels at its Colmenar Viejo facility and successfully transitioned to transporting marine samples exclusively by sea. Additionally, the company's subsidiary, Sylentis, obtained Good Manufacturing Practice (GMP) certification for its new oligonucleotide production plant in Getafe.
Company: Pharma Mar SA
Sector: Manufacturing
Country: Spain
Year: 2025
Type: SR
Pages: 154
Pharma Mar SA
The report details Pharma Mar's sustainability performance and non-financial disclosures for the fiscal year 2025. Key highlights include the company's progress under its Net Zero Plan, achieving a 28.9% reduction in Scope 1 and 2 emissions compared to the 2021 base year. Pharma Mar also expanded its renewable energy capacity by installing 630 kWp of additional solar panels at its Colmenar Viejo facility and successfully transitioned to transporting marine samples exclusively by sea. Additionally, the company's subsidiary, Sylentis, obtained Good Manufacturing Practice (GMP) certification for its new oligonucleotide production plant in Getafe.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees